18,488 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Varma Mutual Pension Insurance Co

Varma Mutual Pension Insurance Co purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,488 shares of the biopharmaceutical company’s stock, valued at approximately $11,528,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Orbimed Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $11,358,000. Lockheed Martin Investment Management Co. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $2,702,000. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $5,682,636,000. National Pension Service lifted its position in Regeneron Pharmaceuticals by 29.8% in the fourth quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after buying an additional 82,853 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $10,472,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $834.04 on Monday. The firm’s 50 day moving average is $697.09 and its two-hundred day moving average is $716.46. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $847.00. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $85.87 billion, a P/E ratio of 20.61, a P/E/G ratio of 1.42 and a beta of 0.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the business earned $12.81 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the sale, the director directly owned 603 shares of the company’s stock, valued at approximately $482,400. This represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is owned by insiders.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Analyst Ratings Changes

A number of research firms have recently issued reports on REGN. Canaccord Genuity Group reduced their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Finally, Wells Fargo & Company increased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $801.70.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.